Business
Successful Clinical Trial of Genedrive®
Successful Clinical Trial of Genedrive®.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 9493W Epistem Holdings plc 03 May 2016 \n\n \n \n \nRNS Press Release\nFor release: 3 May 2016\n \nSuccessful Clinical Trial validates use of Genedrive® in Human Genotyping Application\n \nExternal Validation for Rapid Detection of Genetic Polymorphisms\n \nEpistem Holdings Plc (LSE: EHP), the molecular diagnostics, personalised medicine and biotechnology company, today announces the successful completion of an independent clinical trial of its Genedrive® point of care IL28B SNP human genotyping test. The clinical trial was conducted by teams from the Institut Pasteur and Hopital Cochin, Paris in the context of the FP7 funded PoC-HCV project (www.poc-hcv.eu).\n \nThe clinical trial showed that the Genedrive® human genotyping IL28B SNP test was 100% accurate in detecting inherited genetic polymorphisms in Hepatitis (HCV) patients when compared to the current 'gold-standard' laboratory test (Roche TaqMan® PCR). Genedrive® produces results in 50 minutes from a simple cheek (buccal) swab compared to the standard approach which uses a blood sample and which can have a service lab return time of 2-3 weeks for results.\n \nDavid Budd, CEO of Epistem, commented: \"The result from this clinical trial is excellent external validation of our Genedrive® device both as a robust diagnostic system and as a technology platform in the rapidly growing field of pharmacogenomics and follows on from our recently announced launch in India of our tuberculosis and antibiotic resistance test. As medicine becomes more personalised, there is an increasing need to detect genetic differences in patients. We have efficiently demonstrated Genedrive®'s ability to undertake rapid genotyping in a simple manner. This performance study allows us to initiate opportunities for collaboration with pharmaceutical partners in developing companion diagnostic tests for drug development and patient stratification.\"\n \nDr Darragh Duffy, programme coordinator of the EU FP7 PoC-HCV programme, said: \"Our study recruited 246 HCV patients of different stages and genotypes. The primary endpoint was accuracy of detection in the IL28B gene of CC genotype versus non-CC compared to the TaqMan® Allelic Discrimination Assay. The secondary endpoint was accuracy of detection of CC, CT and TT genotypes again ver...